1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The exploration of GLP-1 receptor agonists for weight loss in end-stage heart failure patients awaiting heart transplantation carries profound implications for clinical practice and patient access to life-saving proce…
GLP-1 analogues could represent a novel, dual-benefit therapeutic option for patients with psoriasis who also contend with obesity or metabolic syndrome. This research suggests a new avenue for treatment, moving beyon…
Liraglutide's efficacy for glycemic control was compared against metformin monotherapy and metformin/glimepiride combination in 1091 Type 2 Diabetes patients.
Should this trial demonstrate that Insulin Degludec/Liraglutide (IDegLira) significantly improves Time in Range while simultaneously reducing markers of inflammation and endothelial dysfunction compared to a tradition…
Clinical trial NCT01451905 aims to characterize GLP-1 receptors in psoriatic skin and evaluate liraglutide for reducing psoriasis severity.
A completed observational study (NCT07374445) explored optimal liraglutide timing for patients remaining obese six months post-metabolic surgery.
For patients with severe insulin resistance in Type 2 Diabetes, optimizing glycemic control without excessive insulin burden is a critical challenge. High insulin doses often lead to weight gain and hypoglycemia, limi…
Phase 1 trial to compare Cagrilintide B (with placebo semaglutide I) and Cagrilintide D blood levels in 234 adults with overweight or obesity over 17 weeks.
A higher-dose oral semaglutide could significantly impact obesity and overweight management by offering a potent, non-injectable alternative to existing therapies. Oral semaglutide 25 mg could provide enhanced conveni…
This trial directly confronts a significant challenge in GLP-1 therapy: mitigating the loss of lean muscle and bone mass during substantial weight reduction. If successful, the findings could establish a new, integrat…
This completed Phase II study for BI 456906 is a crucial step in developing new treatments for Type 2 Diabetes Mellitus and obesity. If positive, the findings could identify optimal dosing strategies for a novel compo…
If successful, this trial could establish semaglutide as a crucial adjunct therapy for individuals with Double Diabetes, potentially improving glycemic control beyond insulin alone and reducing overall insulin require…
A completed Phase 3 trial (NCT04074161) compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily for weight management in overweight/obese adults over 68 weeks.
If successful, the ARO-INHBE trial could introduce a novel therapeutic mechanism for obesity and type 2 diabetes mellitus (T2DM), potentially offering an alternative or complementary option to existing GLP-1 receptor …
A completed Phase 1 study characterized tirzepatide pharmacokinetics in 32 participants with normal to severe hepatic impairment after a single 5 mg SC dose.
Clarifying the link between semaglutide and NAION is critical for patient counseling and prescribing practices. If a significant association is confirmed, it could lead to updated guidelines for monitoring ocular heal…
This review provides crucial insights for peptide users and clinicians, clarifying why dual GLP-1R/GIPR agonists like tirzepatide offer superior weight loss and metabolic improvements over single GLP-1RAs like semaglu…
For nursing mothers prescribed liraglutide, this information highlights a critical knowledge gap: the absence of direct clinical data on infant exposure via breast milk. Clinicians and mothers must exercise caution, e…
Liraglutide and dapagliflozin's six-month effects on lipid profiles, cardiovascular risk, and NT-proBNP in MASLD patients were assessed.
This narrative review highlights the critical need for further research into the effects of GLP-1 agonists on bone health and orthopedic surgery outcomes. Clinicians should be aware of the limited current evidence reg…
This study introduces a powerful SPRM methodology for characterizing peptide-receptor interactions directly on live cells, offering a significant advancement over traditional methods. This label-free, real-time approa…
Liraglutide significantly upregulated GLP1R expression and activated cAMP/PKA signaling, inducing apoptosis and cell cycle arrest in MCF7 breast and PC-3 prostate cancer cells.
Two phase 3, randomized, placebo-controlled trials (evoke and evoke+) investigated oral semaglutide 14 mg for efficacy and safety in early-stage symptomatic Alzheimer's disease.
Authors of the SOUL trial address a comment regarding the impact of oral semaglutide on kidney outcomes in people with type 2 diabetes.
Oral semaglutide 25 mg achieved exposure similar to SC 2.4 mg and led to greater weight loss in simulated studies, according to a meta-analysis.
Semaglutide offers a viable pathway for severely obese ESHF patients to become eligible for life-saving heart transplantation, potentially expanding access to this critical procedure. For clinicians, this suggests int…
Tirzepatide's real-world efficacy in improving sleep-disordered breathing offers a significant practical takeaway for clinicians and individuals managing obesity and type 2 diabetes. Beyond weight loss and glycemic co…
This case underscores the critical importance for clinicians to maintain a high index of suspicion for euglycemic ketoacidosis in patients using tirzepatide, even with normal blood glucose levels. The severe presentat…
Understanding patient and provider preferences for tirzepatide and CPAP in obesity and OSA is critical for optimizing treatment strategies and improving adherence. If patients show a strong preference for a pharmacolo…
This research significantly expands the potential therapeutic scope of Tirzepatide beyond its established roles in type 2 diabetes and obesity, suggesting a novel application in neurodegenerative diseases like Alzheim…
The findings from this cost-effectiveness analysis could profoundly impact treatment paradigms for HFpEF patients with obesity in Germany. If tirzepatide demonstrates superior cost-effectiveness, it could become a cor…
This finding offers a promising new therapeutic avenue for managing Fabry disease, particularly for patients experiencing residual proteinuria despite current standard-of-care treatments. DUAL GIP/GLP-1Ra could signif…
Updated 2026 guidelines for obesity and type 2 diabetes mellitus emphasize the crucial role of modern GLP-1 analogues and tirzepatide in comprehensive management.
This research offers a crucial shift in the narrative around GLP-1RA discontinuation, suggesting that weight regain is not an inevitable outcome for all patients. For individuals considering or undergoing GLP-1RA ther…
This Phase 3 trial represents a crucial step in exploring Liraglutide as an adjunctive therapy for Type 1 Diabetes, a population with significant unmet needs beyond insulin. If the study's hypotheses were confirmed, i…
This foundational dataset provides an unprecedented tool for understanding diabetic microvascular disease at a systemic level, moving beyond organ-specific views. For researchers and clinicians, it offers a quantitati…
If GLP-1R agonists are found to significantly reduce Lipoprotein(a) (Lp(a)) levels, it would represent a substantial advancement in managing cardiovascular risk for Type 2 Diabetes patients. This finding would add a n…
Effective strategies for weight loss maintenance are crucial, as regain is a major challenge in obesity management. This trial's design, focusing on subjects who already achieved initial weight loss through diet, dire…
Optimizing CagriSema dosing could expand treatment options for obesity by identifying regimens that balance efficacy with improved tolerability, potentially leading to broader patient adoption and adherence. Finding e…
A randomized trial will compare semaglutide, tirzepatide, and metformin in 66 obese adults to assess their impact on genetic aging over 24 weeks.
Understanding the intricate link between gut microbiota composition and semaglutide responsiveness could usher in a new era of personalized obesity treatment. If specific microbial profiles are found to predict who wi…
If this trial demonstrates that Semaglutide can effectively prevent or mitigate metabolic deterioration in patients on antipsychotics, it would represent a significant clinical breakthrough. Schizophrenia patients oft…
If successful, this trial could establish tirzepatide as a novel therapeutic option for Long COVID, addressing a critical gap in treatment. The remote, decentralized design of the study is particularly significant, de…
This research suggests a novel therapeutic strategy for hypertension and hyperaldosteronism by combining a GLP-1R agonist with a PDE4 inhibitor. Combining liraglutide with roflumilast could offer enhanced cardiovascul…
Comprehensive understanding of GLP-1RA reproductive safety is paramount for women of reproductive age managing obesity or type 2 diabetes. This review underscores the necessity for robust research to establish clear g…
This finding is highly significant for individuals undergoing GLP-1 receptor agonist therapy, as it addresses a major concern: muscle loss. Combining GLP-1RAs with 15-PGDH inhibitors could preserve muscle mass and imp…
This real-world study provides crucial validation that tirzepatide effectively promotes meaningful weight loss in both Type 2 Diabetes and non-diabetic obese adults, reinforcing its broad utility. The observed glycemi…
This discovery suggests HDM1005 could represent a significant advancement in treating metabolic disorders, potentially offering enhanced efficacy and a more convenient dosing schedule due to its extended half-life. Fo…
This Phase 2 study is crucial for understanding the potential of liraglutide (a GLP-1 receptor agonist) as a combination therapy for Type 2 Diabetes. The findings, once fully published, could highlight a more effectiv…